|
WO2021010893A1
|
|
Cervicovaginal fluid collection device
|
|
WO2020256641A1
|
|
Shoulder rehabilitation device and method
|
|
WO2020256642A1
|
|
A guidewire management device
|
|
WO2020236084A1
|
|
Molecular design of new antibiotics and antibiotic adjuvants against mcr strains
|
|
US2020384083A1
|
|
Treatment and prevention of metabolic diseases
|
|
TW202102207A
|
|
Biomarker with therapeutic implications for carcinomatosis
|
|
WO2020180257A1
|
|
Threonine166 and serine189 of rubicon run domain as lrrk2 kinase inhibition target sites
|
|
WO2020180249A1
|
|
Therapy for dry eye (de) and meibomian gland dysfunction (mgd) based on the replacement of o-acyl-ω-hydroxy fatty acids (oahfa)
|
|
GB202002030D0
|
|
Treatment and prevention of metabolic diseases
|
|
GB202001896D0
|
|
Treatment and prevention of metabolic diseases
|
|
WO2020167250A1
|
|
Device for skin biopsy
|
|
WO2020162834A1
|
|
Method and system for classification and visualisation of 3d images
|
|
GB202001013D0
|
|
Treatment and prevention of metabolic diseases
|
|
US2020262910A1
|
|
Treatment of hepatotoxicity
|
|
WO2020086002A1
|
|
Device and method for ophthalmic extraction and injection
|
|
GB201915003D0
|
|
Treatment of hepatotoxicity
|
|
WO2020072004A2
|
|
Method of predicting treatment response
|
|
WO2020060495A1
|
|
Conductive microneedle patch for active agent delivery
|
|
SG10201907137RA
|
|
Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders
|
|
GB201907839D0
|
|
Treatment of hepatotoxicity
|
